%0 Journal Article %A Pai, Deeksha R. %A Madhugiri Prakash, Venkatesh %A Kumar, T. M. Pramod %D 2019 %I Begell House %K rheumatoid arthritis, molecular targets, targeted delivery, nanocarriers, novel therapy %N 6 %P 485-536 %R 10.1615/CritRevTherDrugCarrierSyst.2019025729 %T Current Developments in Therapeutic Drug Targeting for the Management of Rheumatoid Arthritis: An Emerging Paradigm %U https://www.dl.begellhouse.com/journals/3667c4ae6e8fd136,077131d95cffda98,74f131e6062ca646.html %V 36 %X Rheumatoid arthritis (RA) is a debilitating condition that results in impairment of joints and ligaments and thus constrained mobility and decreased array of movement. It is a broad expression that encompasses additional 100 very diverse disorders mainly affecting joints. In the field of drug discovery, there is no well-known treatment for RA that can eradicate the disease permanently and alleviate the pain. The common non-targeted treatment approaches leads to serious side effects and systemic complications for RA patients. Therefore, targeted drug delivery systems, strategies, and diverse therapeutic approach for treatment of RA have gained increasing attention in the past few years. However, with the current understandings, researchers aim at accomplishing complete and long-lasting remission by the development of smart formulations/smart drug-delivery systems. Treatment for RA patients can be more efficient and effective utilizing these smart approaches. The present review focuses on the existing novel drug-delivery systems, strategies, and current trends in the treatment of RA. %8 2019-12-13